-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $114

Benzinga·10/14/2026 13:31:03
Barclays analyst Eliana Merle maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price target from $111 to $114.